Is The Middle East And North Africa The Most Exciting Place In The World To Build AI Healthcare Right Now?

There is a case to be made that the most interesting place to build AI healthcare products right now is the Gulf.

Saudi Arabia’s Vision 2030 and the UAE’s National AI Strategy have both made digital health a strategic priority, embedding AI into national health goals in a way that creates large, coordinated procurement opportunities that Western healthcare markets rarely offer.

The MENA AI-in-healthcare market is projected to grow from approximately $0.6 billion today to multi-billion levels by the mid-2030s, with some forecasts pointing toward $15 billion by 2035. The capital available to fund that journey, from sovereign wealth funds, government programmes and increasing private investment, is substantial.

The question is whether the regional ambition will translate into the kind of deployments that create lasting commercial and clinical value.

What Is Already Being Built

These deployments are live and operating at scale. The UAE has invested in national AI diagnostics infrastructure capable of processing millions of tests with real-time analysis. Saudi Arabia’s Health Sector Transformation Programme is embedding AI across clinical care pathways, backed by Vision 2030 funding and platforms like Sehhaty that are accelerating digital access.

AI-assisted triage, remote patient monitoring, diagnostic imaging automation and AI for insurance claims processing are all in active use or advanced pilots across the Gulf and North Africa, according to reporting from Saudi Healthcare Consulting.

The high level of clinical demand makes the region an ideal testing ground. Three in five clinicians in the Middle East and Africa are seeing more patients than a year ago, higher than any other region surveyed globally, according to Elsevier’s 2026 Clinician of the Future report, which surveyed 2,757 clinicians across 118 countries. More than half of MENA clinicians report that tiredness has impaired their ability to treat patients effectively – the second-highest rate globally.

The pressure on clinical capacity is severe, and the appetite for tools that address it runs correspondingly high.

The Leapfrog Opportunity

Comparing this to mobile payments is useful – parts of the Middle East and Africa skipped the traditional banking infrastructure layer entirely and moved straight to mobile-first financial services.

The same dynamic may apply to healthcare AI: in markets where legacy electronic health record systems are less entrenched, where government procurement can move at national scale, and where the political will to invest is strong, the path from pilot to deployment can be shorter than in Europe or the US.

Three structural factors make MENA distinctive. The first is policy and procurement muscle: centralised national programmes mean buyers and funding are concentrated, shortening the sales cycle for proven AI products. The second is capital availability: sovereign and state-backed funds provide patient capital that can support clinical validation and scale-up, which is critical for healthcare AI commercialisation. The third is unmet need: wide variation in access to specialists creates demand for remote monitoring, AI triage and diagnostic automation that can produce high impact rapidly.

Where The Gaps Still Are

The outlook is varied – Elsevier’s 2026 Clinician of the Future report finds that clinical-specific AI tool adoption in the Middle East and Africa is the lowest of any global region: just 21% of clinicians who use AI in the region use clinical-specific tools frequently or always, compared to 41% in North America. A quarter of MEA clinicians never use clinical-specific AI tools at all. The report also finds that “responsible” AI is a top-five confidence factor specific to the Middle East and Africa region – suggesting that trust in AI systems remains a significant barrier to adoption in clinical settings.

Regulation and data governance are evolving quickly but remain uneven across countries. Faster movement doesn’t always translate into mature, predictable rules for AI safety, liability and cross-border data flows. Talent and clinical validation capacity are concentrated in a few hubs – Dubai, Abu Dhabi, Riyadh – and scaling clinical evidence across diverse populations will require investment in local trials and genuine partnerships with regional health systems, not just government procurement agreements.

The Hardware Layer

A less-explored facet of AI in MENA healthcare is the physical technology enabling it.

Forat El-Sayed, Business Development Director for the Middle East at Paragraf, a graphene technology company that recently opened an office in Abu Dhabi, puts it directly: “The future of AI-powered healthcare won’t be driven by software alone, but by the physical technologies that allow AI systems to collect better, faster and more accurate real-world data.”

Paragraf is developing graphene-based sensor technologies that can detect biological markers or changes in magnetic fields with high precision and near real-time feedback – providing the kind of high-quality input data that makes AI diagnostic systems more accurate. El-Sayed notes that as countries across the region continue to invest in health tech, the UAE is emerging as an important hub for advanced technology in healthcare innovation, with growing momentum for companies operating at the intersection of materials science and clinical AI.

The combination – ambitious national strategy, available capital, genuine clinical need and an emerging hardware innovation layer – makes MENA one of the more interesting AI healthcare markets to watch in 2026 onwards.

The vision is set, funding is secured, and deployment is underway. MENA’s AI healthcare story is still being written, and the early chapters are more compelling than most of the world has noticed.